Overall survival by relapsed/refractory status
| . | MDACC (n = 165) . | IA/MC (n = 82) . | LY.12 (CCTG) (n = 219) . | CORAL (LYSARC) (n = 170) . | Pooled (N = 636) . |
|---|---|---|---|---|---|
| Patients evaluated for survival, n | 165 | 72 | 196 | 170 | 603 |
| Survival from start of salvage therapy | |||||
| Deaths | 89 | 92 | 80 | 80 | 84 |
| Median, mo (95% CI) | 6.6 | 5.0 | 6.6 | 6.5 | 6.3 (5.9-7.0) |
| 1-y survival rate | 28 | 18 | 31 | 30 | 28 (25-32) |
| 2-y survival rate | 17 | 10 | 23 | 22 | 20 (16-23) |
| Primary refractory | |||||
| Deaths | — | 90 | 76 | 85 | 80 |
| Median, mo (95% CI) | — | 6.1 | 7.9 | 7.3 | 7.1 (6.0-8.1) |
| 1-y survival rate | — | 26 | 30 | 27 | 29 (22-36) |
| 2-y survival rate | — | 21 | 27 | 16 | 24 (18-30) |
| Refractory to second-line or greater therapy | |||||
| Deaths | 88 | 92 | 86 | 77 | 85 |
| Median, mo (95% CI) | 6.6 | 4.7 | 5.3 | 6.1 | 6.1 (5.2-7.0) |
| 1-y survival rate | 29 | 9 | 24 | 30 | 26 (22-31) |
| 2-y survival rate | 19 | 6 | 14 | 22 | 17 (13-22) |
| Relapse at 12 months post-ASCT or earlier | |||||
| Deaths | 94 | 94 | 86 | 80 | 86 |
| Median, mo (95% CI) | 5.9 | 4.2 | 7.0 | 6.5 | 6.2 (5.2-7.6) |
| 1-y survival rate | 19 | 25 | 38 | 34 | 32 (24-41) |
| 2-y survival rate | 6 | 6 | 21 | 26 | 19 (12-27) |
| . | MDACC (n = 165) . | IA/MC (n = 82) . | LY.12 (CCTG) (n = 219) . | CORAL (LYSARC) (n = 170) . | Pooled (N = 636) . |
|---|---|---|---|---|---|
| Patients evaluated for survival, n | 165 | 72 | 196 | 170 | 603 |
| Survival from start of salvage therapy | |||||
| Deaths | 89 | 92 | 80 | 80 | 84 |
| Median, mo (95% CI) | 6.6 | 5.0 | 6.6 | 6.5 | 6.3 (5.9-7.0) |
| 1-y survival rate | 28 | 18 | 31 | 30 | 28 (25-32) |
| 2-y survival rate | 17 | 10 | 23 | 22 | 20 (16-23) |
| Primary refractory | |||||
| Deaths | — | 90 | 76 | 85 | 80 |
| Median, mo (95% CI) | — | 6.1 | 7.9 | 7.3 | 7.1 (6.0-8.1) |
| 1-y survival rate | — | 26 | 30 | 27 | 29 (22-36) |
| 2-y survival rate | — | 21 | 27 | 16 | 24 (18-30) |
| Refractory to second-line or greater therapy | |||||
| Deaths | 88 | 92 | 86 | 77 | 85 |
| Median, mo (95% CI) | 6.6 | 4.7 | 5.3 | 6.1 | 6.1 (5.2-7.0) |
| 1-y survival rate | 29 | 9 | 24 | 30 | 26 (22-31) |
| 2-y survival rate | 19 | 6 | 14 | 22 | 17 (13-22) |
| Relapse at 12 months post-ASCT or earlier | |||||
| Deaths | 94 | 94 | 86 | 80 | 86 |
| Median, mo (95% CI) | 5.9 | 4.2 | 7.0 | 6.5 | 6.2 (5.2-7.6) |
| 1-y survival rate | 19 | 25 | 38 | 34 | 32 (24-41) |
| 2-y survival rate | 6 | 6 | 21 | 26 | 19 (12-27) |
Values shown as percentages, unless otherwise indicated. Hazard ratios (HRs) have been calculated from a Cox proportional hazards model (stratified by center). Second-line refractory vs primary refractory, HR, 1.24 (P = .17). Relapsed ≤12 months after ASCT vs primary refractory, HR, 1.20 (P = .17).